aXichem and LIFEPro Nutrition to collaborate in study on aXivite, conducted at the University of Pablo Olavide – High Performance Centre, evaluating sports performance effect in athletes
May 16, 2022
aXichem and LIFEPro Nutrition to collaborate in study on aXivite, conducted at the University of Pablo Olavide – High Performance Centre, evaluating sports performance effect in athletes

aXichem AB (publ), that develops and markets natural analogue industrial compounds, announces that aXivite®, the company’s food supplement and nutrition ingredient product, will be evaluated in a trial with elite athletes to determine the effect of phenylcapsaicin on physical performance. The trial will be carried out in collaboration with the Spanish companies LIFEPro Nutrition and Indiex Sport Nutrition and conducted at University of Pablo Olavide - High Performance Center (CIRFED), which is one of the most prestigious universities related to resistance training worldwide.

“aXivite is right now gaining a lot of positive attention and we are getting more and more orders for product development from our distributors. The study with LIFEPro Nutrition and the goal to, for the first time, map the impact of capsaicin, or capsaicin analogues, on processes in the body during exercise, such as biochemical metabolic responses and muscle damage, fits very well into our commercial plan for aXivite. Together with LIFEPro, and a team of highly skilled and professional researchers and athletes, I’m looking forward to the outcome and data from the study. I believe that aXivite has a huge potential in the sportssegment, says Lucas Altepost, VP and Chief Sales and Marketing Officer at aXichem.

About the study
Oral capsaicinoids and capsinoids supplements have previously been studied for a plausible ergogenic impact on sports performance. The purpose of performed systematic review was to explore the effects of capsaicinoids and capsinoids on resistance training and high intensity interval training (HIIT). As aXichem’s phenylcapsaicin is more bioavailable than natural capsaicin, is the study carried out under aXichem’s collaboration with LIFEPro and Indiex designed as a three-branched randomized double blind controlled trial. In the trial, biochemical parameters related to muscle damage, metabolic response and myoelectrical variables will be measured. Sport performance outcomes will be related to some of the most validated tests, well proven in trials of this kind. Participants will be 30 healthy, highly trained male athletes, with previous experience from trials and test situations. The study will be conducted on Universidad Pablo Olavide (UPO), Seville, Spain, in collaboration with University of Valencia, Madrid Autonomous University and National School of Strength and Physical Conditioning (ENFAF) researchers.

The trial is expected to start in the third quarter 2022 and be finalized during the year.

Indiex Sport Nutrition is one of Spain’s leading manufacturers and suppliers of nutrition products, specifically targeting the market for sports and fitness. Indiex has direct sales to consumers as well as to resellers with known brands such as LifePro Nutrition in their portfolio.

More about aXivite®
aXivite is a natural analogue product, developed to fit as a component in food supplement and nutrition products. aXivite is an adjusted version of aXichem’s synthetically produced and patented capsacin, aXiphen®. Since the product is synthetically produced the substance has a number of advantages compared to natural capsaicin. The main difference is that natural capsaicin is extracted from chili and therefore varies in quality and seldom reaches a concentration above 85 percent. aXiphen® holds a concentration of at least 97 percent and has predictable characteristics. One of the key industrial benefits with the product is that aXichem can determine its water- and fat solubility, which is critical when using the substance in various kinds of products. aXiphen has a GRAS food clearance in the U.S. and a Novel Food approval for the EU.

The information was submitted, through the care of the contact person, for publication on May 16, 2022, at 08:40 AM CEST.